Intellia Therapeutics Inc. (NASDAQ: NTLA) is 47.48% higher on its value in year-to-date trading and has touched a low of $11.06 and a high of $92.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NTLA stock was last observed hovering at around $80.06 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $80.00 for the next 12 months. It is also 27.72% off the consensus price target high of $111.00 offered by 15 analysts, but current levels are -264.68% lower than the price target low of $22.00 for the same period.
Currently trading at $80.23, the stock is 23.84% and 22.26% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.87 million and changing 0.21% at the moment leaves the stock 99.43% off its SMA200. NTLA registered 574.20% gain for a year compared to 6-month gain of 299.35%. The firm has a 50-day simple moving average (SMA 50) of $64.28 and a 200-day simple moving average (SMA200) of $49.58.
The stock witnessed a 47.43% loss in the last 1 month and extending the period to 3 months gives it a 47.48%, and is 23.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.91% over the week and 11.47% over the month.
Intellia Therapeutics Inc. (NTLA) has around 312 employees, a market worth around $5.45B and $58.00M in sales. Distance from 52-week low is 625.41% and -12.79% from its 52-week high.
Intellia Therapeutics Inc. (NTLA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Intellia Therapeutics Inc. (NTLA) is a “Overweight”. 15 analysts offering their recommendations for the stock have an average rating of 2.20, where 5 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Intellia Therapeutics Inc. is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.67 with sales reaching $8.57M over the same period.The EPS is expected to shrink by -13.80% this year, but quarterly earnings will post -35.20% year-over-year.
Intellia Therapeutics Inc. (NTLA) Top Institutional Holders
344 institutions hold shares in Intellia Therapeutics Inc. (NTLA), with 6.2M shares held by insiders accounting for 9.15% while institutional investors hold 91.20% of the company’s shares. The shares outstanding are 61.29M, and float is at 52.88M with Short Float at 16.53%. Institutions hold 82.86% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 11.19 million shares valued at $608.83 million. The investor’s holdings represent 16.52% of the NTLA Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 5.13 million shares valued at $279.14 million to account for 7.58% of the shares outstanding. The other top investors are Nikko Asset Management Americas, Inc. which holds 5.1 million shares representing 7.54% and valued at over $277.68 million, while Sumitomo Mitsui Trust Holdings, Inc. holds 7.54% of the shares totaling 5.1 million with a market value of $277.68 million.
Intellia Therapeutics Inc. (NTLA) Insider Activity
A total of 84 insider transactions have happened at Intellia Therapeutics Inc. (NTLA) in the last six months, with sales accounting for 51 and purchases happening 33 times. The most recent transaction is an insider sale by LEONARD JOHN M ,the company’sPresident and CEO. SEC filings show that LEONARD JOHN M sold 38,209 shares of the company’s common stock on Apr 01 at a price of $83.64 per share for a total of $3.2 million. Following the sale, the insider now owns 0.68 million shares.
Intellia Therapeutics Inc. disclosed in a document filed with the SEC on Apr 01 that Rivera Jose E (EVP, General Counsel) sold a total of 50,455 shares of the company’s common stock. The trade occurred on Apr 01 and was made at $82.46 per share for $4.16 million. Following the transaction, the insider now directly holds 0.13 million shares of the NTLA stock.
Still, SEC filings show that on Feb 26, FORMELA JEAN FRANCOIS (Director) disposed off 501,945 shares at an average price of $60.29 for $30.26 million. The insider now directly holds 1,113,376 shares of Intellia Therapeutics Inc. (NTLA).
Intellia Therapeutics Inc. (NTLA): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading 22.64% up over the past 12 months. Short interest in the company’s stock has risen 1.95% from the last report on Feb 11, 2021 to stand at a total of 8.57 million short shares sold with a short interest ratio of 5.31.